In August 2017, in a randomized, pivotal, phase 3 study of KEYNOTE-024 (ClinicalTrials.gov Identifier: NCT02142738), pembrolizumab, a PD1 inhibitor, was approved by FDA as a first-line therapy for advanced metastatic (stage IV) NSCLC, according to PD-L1 expression status of the tumor, giving superior progression-free survival in comparison to platinum-based therapy. Here, CD274 is linked to non-small cell lung carcinoma.